Anzeige
Mehr »
Login
Montag, 25.09.2023 Börsentäglich über 12.000 News von 674 internationalen Medien
Der Zeitpunkt für den Einstieg ist gekommen. Hier ist der optimale Uran-Hebel!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LGJ2 | ISIN: FR0004163111 | Ticker-Symbol: XUP
Tradegate
25.09.23
10:13 Uhr
3,180 Euro
-0,010
-0,31 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GENFIT SA Chart 1 Jahr
5-Tage-Chart
GENFIT SA 5-Tage-Chart
RealtimeGeldBriefZeit
3,0303,03512:06
3,0253,05512:06

Aktuelle News zur GENFIT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiGenfit S.A. - 6-K, Report of foreign issuer1
MiGenfit GAAP EPS of -€0.42, revenue of €15.37M1
MiGENFIT S.A.: GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update191Cash, cash equivalents and current financial assets totaled €111.8 million as of June 30, 2023 Positive results in the pivotal Phase 3 ELATIVE® trial in June 2023, paving the way to: a potential submission...
► Artikel lesen
07.09.DelveInsight Business Research, LLP: Acute-On-Chronic Liver Failure Market to Register Immense Growth by 2032, Assesses DelveInsight | Key Companies - Grifols, Promethera, GENFIT, RHEACELL, Versantis, Martin GNI Group486The dynamics of the acute-on-chronic liver failure market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease...
► Artikel lesen
07.09.Genfit, CymaBay, Palisade among healthcare movers3
05.09.GENFIT S.A.: GENFIT to Participate in Upcoming Investor Conferences2
10.08.GENFIT S.A.: GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+ in Older Patients in Hepatology Communications4
31.07.Celloram, GENFIT Partner on CLM-022 in Liver Disease5
12.07.Genfit S.A. - 6-K, Report of foreign issuer3
12.07.GENFIT S.A.: GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial6
03.07.Analyst Expectations for Genfit's Future9
30.06.Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class20
30.06.Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients7
30.06.Genfit rises after liver disease treatment meets late-stage study goal5
30.06.Genfit soars 23% as Phase 3 trial for liver disease candidate succeeds5
30.06.Genfit and Ipsen announce elafibranor results4
30.06.Ipsen, Genfit report phase 3 rare liver disease success, setting up showdown with Intercept3
30.06.Genfit S.A. - 6-K, Report of foreign issuer1
30.06.Ipsen, GENFIT Reveal Positive Phase III Trial Results Of Elafibranor In Patients With PBC6
30.06.Ipsen Pharma: Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease451Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to placebo Elafibranor was well tolerated with...
► Artikel lesen
Seite:  Weiter >>
41 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1